SIAXI: Efficacy and safety of incobotulinumtoxinA for the treatment of sialorrhea in Parkinson's disease (PD) and other neurological conditions: results of a Phase III, placebo-controlled, randomised, doubleblind study

被引：0
作者：
Csikos, J. [1 ]
Blitzer, A. [2 ]
Friedman, A. [3 ]
Michel, O. [4 ,5 ]
Flatau-Baque, B. [6 ]
Jost, W.
机构：
[1] Merz Pharmaceut, Frankfurt, Germany
[2] Columbia Univ Coll Phys & Surg, Dept Otolaryngol Head & Neck Surg, 630 W 168th St, New York, NY 10032 USA
[3] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA
[4] Med Univ Warsaw, Dept Neurol, Fac Hlth Sci, Warsaw, Poland
[5] Univ Hosp Brussels, Otorhinolaryngol, Brussels, Belgium
[6] Parkinson Klin Wolfach, Wolfach, Germany
来源：
INTERNATIONAL JOURNAL OF STROKE | 2018年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [41] Clinical efficacy of istradefylline (KW-6002) in the treatment of Parkinson's disease: A randomized placebo-controlled study
    Mizuno, Y.
    Kuno, S.
    Yamamoto, M.
    Hasegawa, K.
    Kondo, T.
    MOVEMENT DISORDERS, 2009, 24 : S269 - S269
  • [42] OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy
    Taylor, Peter C.
    Genovese, Mark C.
    Greenwood, Mike
    Ho, Meilien
    Nasonov, Evgeny
    Oemar, Barry
    Stoilov, Rumen
    Vencovsky, Jiri
    Weinblatt, Michael
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (12) : 2123 - 2129
  • [43] OSKIRA-4: A PHASE IIB RANDOMISED, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF FOSTAMATINIB MONOTHERAPY
    Taylor, P. C.
    Genovese, M. C.
    Greenwood, M.
    Ho, M.
    Nasonov, E.
    Oemar, B.
    Stoilov, R.
    Vencovsky, J.
    Weinblatt, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 66 - 66
  • [44] A Meta-Analysis of Randomised Placebo-Controlled Treatment Trials for Depression and Anxiety in Parkinson's Disease
    Troeung, Lakkhina
    Egan, Sarah J.
    Gasson, Natalie
    PLOS ONE, 2013, 8 (11):
  • [45] Efficacy of IncobotulinumtoxinA for treatment of glabellar frown lines: A post hoc pooled analysis of 2 randomized, placebo-controlled phase III trials
    Jones, Derek
    Brandt, Fredric
    Carruthers, Jean
    Cohen, Joel
    Narins, Rhoda
    Coleman, William
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB15 - AB15
  • [46] PF-06649751 efficacy and safety in early Parkinson's disease: a randomized, placebo-controlled trial
    Riesenberg, Robert
    Werth, John
    Zhang, Yao
    Duvvuri, Sridhar
    Gray, David
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
  • [47] IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From Two Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
    Joseph, John
    Sudimac, Vladimir
    Mersmann, Sabine
    Kerscher, Martina
    AESTHETIC SURGERY JOURNAL, 2024, 45 (03) : 293 - 304
  • [48] Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study
    Ballard, Clive
    Banister, Carol
    Khan, Zunera
    Cummings, Jeffrey
    Demos, George
    Coate, Bruce
    Youakim, James M.
    Owen, Randall
    Stankovic, Srdjan
    LANCET NEUROLOGY, 2018, 17 (03) : 213 - 222
  • [49] Double blind, randomised, placebo controlled study to compare the safety, tolerance and efficacy of pramipexole and bromocriptine in advanced Parkinson's disease
    Guttman, M
    NEUROLOGY, 1997, 48 (03) : 32003 - 32003
  • [50] A Randomized, Placebo-Controlled, Double-Blind Phase III Trial Investigating the Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Glabellar Frown Lines Using a Stringent Composite Endpoint
    Hanke, C. William
    Narins, Rhoda S.
    Brandt, Fredric
    Cohen, Joel L.
    Donofrio, Lisa M.
    Downie, Jeanine
    Heinz, Moritz
    Harrington, Laura
    McDaniel, David H.
    Nestor, Mark
    Schlessinger, Joel
    Schloebe, Andrea
    Taub, Amy
    Weiss, Robert A.
    DERMATOLOGIC SURGERY, 2013, 39 (06) : 891 - 899
12345